Global state: clinically important change in global state needing additional medication ‐ chlorpromazine · patients with schizophrenia
It is very uncertain whether α‐FLUPENTHIXOL changes global state: clinically important change in global state needing… compared with PLACEBO or β‐FLUPENTHIXOL (very low certainty).
1 finding from 1 review
Mental state and behaviour: clinically important change in general mental state and behaviour · patients with schizophrenia
1 finding from 1 review
Adverse effects/events: incidence of adverse effects/events · patients with schizophrenia
1 finding from 1 review
Hospital admissions · patients with schizophrenia
1 finding from 1 review
General functioning: Poor social functioning ‐ modified Cooper's ratings5,6 · patients with schizophrenia
It is very uncertain whether α‐FLUPENTHIXOL changes general functioning: Poor social functioning ‐ modified Cooper's… compared with PLACEBO or β‐FLUPENTHIXOL (very low certainty).
1 finding from 1 review
Satisfaction with treatment: satisfaction with care for recipients of care or careers · patients with schizophrenia
1 finding from 1 review
Economic: direct costs · patients with schizophrenia
1 finding from 1 review
Response to treatment · patients with schizophrenia
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
1 finding from 1 review
Risk for at least one adverse event per patient · patients with schizophrenia
1 finding from 1 review
Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
1 finding from 1 review
Adverse effects ‐ death · patients with schizophrenia
1 finding from 1 review
Quality of life · patients with schizophrenia
1 finding from 1 review
Clinical response: mental state ‐ relapse ‐ medium term Relapse rate · patients with schizophrenia or related psychoses
FLUPENTHIXOL DECANOATE HIGH DOSE showed no clear difference in clinical response: mental state ‐ relapse ‐ medium term Relapse rate compared with FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) (low certainty).
1 finding from 1 review
Mental state · patients with schizophrenia or related psychoses
1 finding from 1 review
Global impression ‐ no improvement ‐ medium term As defined in each study · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short/medium term Rate of attrition · patients with schizophrenia or related psychoses
FLUPENTHIXOL DECANOATE HIGH DOSE may leads to lower leaving the study early ‐ short/medium term Rate of attrition compared with FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) (low certainty).
1 finding from 1 review
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short term Numbers requiring anticholinergic medication · patients with schizophrenia or related psychoses
1 finding from 1 review